+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07066657

Open-Label Phase I Study Evaluating Safety and Pharmacokinetics of MRG007 in Patients with Unresectable Advanced or Metastatic Solid Tumors

Led by ArriVent BioPharma, Inc. · Updated on 2026-08-13

572

Participants Needed

21

Research Sites

143 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, effectiveness, and how the body processes MRG007 ARR-217 in people with advanced solid tumors that cannot be removed by surgery or have spread to other parts of the body. This phase I, open-label, multi-center study focuses on patients who have advanced or metastatic solid tumors such as colorectal, gastric, or pancreatic cancer, particularly those who have not responded to or cannot tolerate standard treatments. Participants receive MRG007 alone or combined with Bevacizumab according to the study protocol. The study uses a sequential design and includes dose escalation, confirmation, and expansion phases. Treatments are administered as specified, and the study monitors participants from the first dose through up to 24 months to assess responses and safety. During the study, participants will be closely monitored for various outcomes including dose-limiting toxicities, serious and treatment-related side effects, and tumor response rates. Assessments include physical exams, laboratory tests, and imaging to measure tumor size according to RECIST criteria. Safety monitoring continues for 30 days after the last dose, and overall survival, disease control, and pharmacokinetics are tracked throughout the study period, which may last until December 2030.

CONDITIONS

Brief Title

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Research Team

C

Clinical Trials

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here